This site is intended for healthcare professionals
CSU Learning Zone

EAACI Digital Congress 2020

Read time: 50 mins
Published:20th Jun 2020

EAACI encourages tackling allergic diseases and asthma at their root, and key to this was the Novartis company-sponsored virtual symposium ‘Breakthrough in the understanding of the anti-IgE pathway in CSU’, co-chaired by Professor Marcus Maurer and PD Dr. Alexander Eggel. 

Professor Maurer begins with an introduction to chronic spontaneous urticaria (CSU) and then hands over to Dr Alexander Eggel who speaks in detail about IgE inhibition in CSU, explaining why not all anti-IgEs are born equal. Professor Maurer then describes the clinical implications of this inequality which helps to explain the differential effects of omalizumab and ligelizumab in CSU and asthma.

Register free for full access to

Developed by EPG Health for Medthority. This content has been developed in collaboration with Novartis Pharma AG. EPG Health received funding from Novartis Pharma AG in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.